Overview

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The study objective is to improve the global results obtained with LAL-AR-93 study, reaching an event free survival between 60-70%. Identify patients with bad prognosis, with minimal residual disease,who can benefit of allogenic bone marrow transplantation
Phase:
Phase 4
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
Asparaginase
Cyclophosphamide
Cytarabine
Daunorubicin
Methotrexate
Prednisolone
Vincristine